Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paltusotine randomized controlled study in acromegaly patients previously treated with long-acting somatostatin receptor ligands
2024-511925-71-00Phase 3Completed
- Sponsor
- Crinetics Pharmaceuticals
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in acromegaly comparing Paltusotine with Placebo comparator (2 arms). Primary endpoint: Maintenance of biochemical response in IGF-1 at end of randomized control phase. Started Sep 2024; status: completed.
02
Drugs
paltusotine
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2024-511925-71-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511925-71-00.